Patient Derived Xenograft (PDX) Models Market

Global Patient Derived Xenograft (PDX) Models Market By Type (Mice Models and Rat Models), Tumor Type (Gastrointestinal Tumor Models, Gynecological Tumor Models, Respiratory Tumor Models, Urological Tumor Models, Hematological Tumor Models, and Others), Application (Preclinical Drug Development, Biomarker Analysis, Basic Cancer Research), End-user (Pharmaceutical & Biotechnology Companies, Contract Research Organizations (CROs), and Academic & Research Institutions), and Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa)

  • Report ID: HC-2512
  • Author: Growth Market Reports
  • Rating: 4.8
  • Total Reviews: 1
  • No. Of Pages: 296
  • Format:
  • Pub. Date: 16-04-2021
  • Share:

Market Outlook:

The Global Patient Derived Xenograft (PDX) Models Market was valued at USD 113.5 Million in 2019 and is anticipated to reach 283.3 Million by 2027, expanding at a CAGR of 14.5% during the forecast period. Patient-derived xenografts (PDX) are models of cancer in which the cells from a patient’s tumor are inserted into an immune deficient or humanized mouse. PDX models simulate that human tumor biology is allowing for natural cancer progression and offers translational research for calculating the desired result. Patient-derived xenograft (PDX) mouse models includes the insertion of fresh human tumor samples directly into the immune-deficient mice by surgery. Xenograft animal models are required for testing the effectiveness of medicines and are mostly required in drug advancement for cancer, diabetes, infections, etc.

Patient Derived Xenograft (PDX) Models Market Key Takeaways

Gene expression in tumors is maintained by sequential path of tumors from mouse to mouse. These models support research for tumor biology and pharmacology deprived of manual influence of cell cultures and are usually used in modified cancer therapy, drug enlargement and clinical tests. PDX models show advanced predictive values for clinical results than cell linederived xenograft models and hereditarily engineered mouse models.

Market Dynamics

The market is driven by factors such as Rising governments support for pharmaceutical and biotechnology industries, growing demand for personalized medicines, increasing R&D activities by pharmaceutical and biotechnology companies, surging number of preclinical studies for developing anti-cancer drugs for solid tumors. Conversely, high cost of personalized PDX models, implementation of stringent guidelines on the use of animal models in cancer research. Rising demand for humanized PDX models is one the major factors anticipated to create lucrative opportunities in the market.

Segmental Outlook

Based on types, the Global Patient Derived Xenograft (PDX) Models Market is fragmented into mice models and rat models. Mice models segment is anticipated to hold the largest market share during the forecast period. Ease of procurement, manipulation, and the minimum facilities required for keeping mice models under observation in comparison to rats is driving the PDX models market. Rising development of biotechnological goods and new medical devices is expected to boost the global patient-derived xenograft (PDX) market. New competitive market players bringing innovative healthcare solutions is anticipated to grow the preclinical testing market, which is expected to increase the demand for rat models. Introduction of immunodeficient rats drives the use of rat models in the PDX models market. Rat models segment is anticipated to boost at a substantial growth rate during the forecast period. Factors which drives this market consists of the larger size of rats, which enhances surgical manipulation.

Patient Derived Xenograft (PDX) Models Market By Types

On the basis of tumor types, the global patient-derived xenografts (PDX) models market is segmented into gynecological tumor models, gastrointestinal tumor models, urological tumor models, respiratory tumor models, hematological tumor models, and other tumor models. The gastrointestinal tumor models segment is anticipated to dominate the global patient-derived xenografts (PDX) models market, due to rising number of gastrointestinal tumor models and growing gastrointestinal tumor research in academic & research institutions and contract research organizations (CROs). The respiratory tumor model segment is expected to grow at the highest rate during the forecast period. Factors attributing to the growth of the segment includes increasing research activities in the oncology field and growing focus of competitive market players on generating lung cancer PDX models, due to increasing number of cancer cases. Funds for companies involved in cancer research are anticipated to grow at a rapid pace during forecast period for the global patient-derived xenografts (PDX) models market.

Patient Derived Xenograft (PDX) Models Market By Tumor Type

Based on applications, the global patient-derived xenografts (PDX) models market is fragmented into preclinical drug development, biomarker analysis, and basic cancer research. Preclinical drug development segment is anticipated to reach the maximum growth rate in the PDX models market during the forecast period. Compound annual growth rate of this segment is attributed to increasing number of clinical tests. The basic cancer research and preclinical drug development segment accounts for a large market share of the global PDX models market. The segment is important, due to rising number of research activities in the oncology drug research field. The basic cancer research disease segment is anticipated to grow at a substantial rate, due to increasing adoption of PDX models for basic cancer research. Basic cancer research is the characterization of cancer biology and exploring mechanisms that are involved for prediction or having a knowledge of cancer.

Patient Derived Xenograft (PDX) Models Market By Application

Based on end-users, the global patient-derived xenograft (PDX) models is fragmented into Pharmaceutical & Biotechnology Companies, Contract Research Organizations (CROs), and Academic & Research Institutions. The academic & research organizations segment dominates the market, as the usage of PDX models is growing for basic cancer research and characterization of cancer biology, tumorigenesis, and metastasis. The contract research organizations segment is anticipated to grow at a high CAGR during the forecast period. Market growth rate in this segment are attributed to rising number of pharmaceutical companies, which outsource preclinical studies to CROs. The pharmaceutical and biotechnology companies segment is growing at a rapid pace, owing to the boost provided by the ongoing pandemic. Market players are focusing on developing new and efficient products to cater to the growing needs of the market. The segment is predicted to grow at a substantial rate.

Patient Derived Xenograft (PDX) Models Market By End User

Regional Outlook

Based on regions, the global Patient Derived Xenograft (PDX) Models market is segregated into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America accounts for a major share of the market, followed by Europe. The market in North America is projected to expand at a significant CAGR during the forecast period, owing to increasing preclinical activities by CROs and pharmaceutical companies and rapid growth in onco-immunology research are some of the factors driving the market in North America. Moreover, the market in Asia Pacific is expected to grow due to rising prevalence of cancer and increasing government expenditure on pharmaceutical R&D. It is also estimated to grow at the highest CAGR in the PDX models market during the forecast period, mainly owing to factors such as increasing trend of outsourcing drug discovery services, and growing life sciences research.

Patient Derived Xenograft (PDX) Models Market By Regions

Key Benefits for Industry Participants & Stakeholders

  • In-depth Analysis of the Global Patient Derived Xenograft (PDX) Models Market
  • Historical, Current and Projected Market Size in terms of Value and Volume
  • Potential & Niche Segments and Regions Exhibiting Promising Growth Covered
  • Industry Drivers, Restraints and Opportunities Covered in the Study
  • Recent Industry Trends and Developments
  • Competitive Landscape & Strategies of Key Players
  • Neutral Perspective on Global Patient Derived Xenograft (PDX) Models Market Performance

Segments

Key Segments Covered
By Type
  • Mice Models
  • Rat Models
By Tumor Type
  • Gastrointestinal Tumor Models
  • Gynecological Tumor Models
  • Respiratory Tumor Models
  • Urological Tumor Models
  • Hematological Tumor Models
  • Others
By Application
  • Preclinical Drug Development
  • Biomarker Analysis
  • Basic Cancer Research
By End-user
  • Pharmaceutical & Biotechnology Companies
  • Contract Research Organizations (CROs)
  • Academic & Research Institutions
By Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Key Market Players Profiled in the Report
  • Abnova Corporation
  • Aragen Bioscience, a GVKBIO Company
  • Bioduro
  • Champions Oncology, Inc.
  • Charles River Laboratories
  • Envigo
  • EPO Berlin-Buch GmbH
  • Explora BioLabs
  • Hera Biolabs
  • NexusPharma
  • Oncodesign
  • THE JACKSON LABORATORY
  • Urosphere
  • WuXi AppTec
  • Xentech

Competitive Landscape

  • Top players in the market include THE JACKSON LABORATORY, WuXi AppTec, Envigo, Oncodesign, and Charles River Laboratories. These companies are considered as key manufacturers of Patient Derived Xenograft (PDX) Models based on their revenue, research development (R&D) activities, product offerings, regional presence, and supply chain management system.
  • The players are adopting key strategies such as acquisition, collaborations, and geographical expansion where potential opportunity for the Patient Derived Xenograft (PDX) Models market.
  • On March 02, 2021, Explora BioLabs launched two facilities in San Diego, in the US. The launch of these facilities is expected to expand Explora BioLabs’s footprints in San Diego from seven to nine on-demand vivaria.
  • On February 25, 2021, Charles River Laboratories, entered into a strategic partnership with Kibur Medical to offer exclusive access to its implantable microdevice (IMD) for in vivo preclinical oncology studies. Through this partnership, together with leading expertise in early-stage preclinical testing, researchers can utilize the Kibur technology to perform in vivo testing of multiple doses and multiple combinations of oncology or immune-oncology therapies in small cohorts of patient-derived xenograft (PDX), cell-line derived or syngeneic models.
  • In January 2021, Endo International plc launched Authorized Generic Version of Amitiza (lubiprostone) Capsules in the US.
Patient Derived Xenograft (PDX) Models Market By Key Players
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Patient Derived Xenograft (PDX) Models Market Overview
   4.1 Introduction
      4.1.1 Market Taxonomy
      4.1.2 Market Definition
      4.1.3 Macro-Economic Factors Impacting the Market Growth
   4.2 Patient Derived Xenograft (PDX) Models Market Dynamics
      4.2.1 Market Drivers
      4.2.2 Market Restraints
      4.2.3 Market Opportunity
   4.3 Patient Derived Xenograft (PDX) Models Market - Supply Chain Analysis
      4.3.1 List of Key Suppliers
      4.3.2 List of Key Distributors
      4.3.3 List of Key Consumers
   4.4 Key Forces Shaping the Patient Derived Xenograft (PDX) Models Market
      4.4.1 Bargaining Power of Suppliers
      4.4.2 Bargaining Power of Buyers
      4.4.3 Threat of Substitution
      4.4.4 Threat of New Entrants
      4.4.5 Competitive Rivalry
   4.5 Global Patient Derived Xenograft (PDX) Models Market Size & Forecast, 2017-2027
      4.5.1 Patient Derived Xenograft (PDX) Models Market Size and Y-o-Y Growth
      4.5.2 Patient Derived Xenograft (PDX) Models Market Absolute $ Opportunity
   4.6 Regulatory Landscape
   4.7 Technology Landscape
   4.8 Patent Analysis
   4.9 Consumer Survey
   4.10 Pipeline /Clinical Trial Analysis

Chapter 5 Global Patient Derived Xenograft (PDX) Models Market Analysis and Forecast By Type
   5.1 Introduction
      5.1.1 Key Market Trends & Growth Opportunities By Type
      5.1.2 Basis Point Share (BPS) Analysis By Type
      5.1.3 Absolute $ Opportunity Assessment By Type
   5.2 Patient Derived Xenograft (PDX) Models Market Size Forecast By Type
      5.2.1 Mice Models
      5.2.2 Rat Models
   5.3 Market Attractiveness Analysis By Type
Chapter 6 Global Patient Derived Xenograft (PDX) Models Market Analysis and Forecast By Tumor Type
   6.1 Introduction
      6.1.1 Key Market Trends & Growth Opportunities By Tumor Type
      6.1.2 Basis Point Share (BPS) Analysis By Tumor Type
      6.1.3 Absolute $ Opportunity Assessment By Tumor Type
   6.2 Patient Derived Xenograft (PDX) Models Market Size Forecast By Tumor Type
      6.2.1 Gastrointestinal Tumor Models
      6.2.2 Gynecological Tumor Models
      6.2.3 Respiratory Tumor Models
      6.2.4 Urological Tumor Models
      6.2.5 Hematological Tumor Models
      6.2.6 Others
   6.3 Market Attractiveness Analysis By Tumor Type
Chapter 7 Global Patient Derived Xenograft (PDX) Models Market Analysis and Forecast By Application
   7.1 Introduction
      7.1.1 Key Market Trends & Growth Opportunities By Application
      7.1.2 Basis Point Share (BPS) Analysis By Application
      7.1.3 Absolute $ Opportunity Assessment By Application
   7.2 Patient Derived Xenograft (PDX) Models Market Size Forecast By Application
      7.2.1 Preclinical Drug Development
      7.2.2 Biomarker Analysis
      7.2.3 Basic Cancer Research
   7.3 Market Attractiveness Analysis By Application
Chapter 8 Global Patient Derived Xenograft (PDX) Models Market Analysis and Forecast By End-user
   8.1 Introduction
      8.1.1 Key Market Trends & Growth Opportunities By End-user
      8.1.2 Basis Point Share (BPS) Analysis By End-user
      8.1.3 Absolute $ Opportunity Assessment By End-user
   8.2 Patient Derived Xenograft (PDX) Models Market Size Forecast By End-user
      8.2.1 Pharmaceutical & Biotechnology Companies
      8.2.2 Contract Research Organizations (CROs)
      8.2.3 Academic & Research Institutions
   8.3 Market Attractiveness Analysis By End-user
Chapter 9 Global Patient Derived Xenograft (PDX) Models Market Analysis and Forecast by Region
   9.1 Introduction
      9.1.1 Key Market Trends & Growth Opportunities by Region
      9.1.2 Basis Point Share (BPS) Analysis by Region
      9.1.3 Absolute $ Opportunity Assessment by Region
   9.2 Patient Derived Xenograft (PDX) Models Market Size Forecast by Region
      9.2.1 North America
      9.2.2 Europe
      9.2.3 Asia Pacific
      9.2.4 Latin America
      9.2.5 Middle East & Africa (MEA)
   9.3 Market Attractiveness Analysis by Region
Chapter 10 Coronavirus Disease (COVID-19) Impact
   10.1 Introduction
   10.2 Current & Future Impact Analysis
   10.3 Economic Impact Analysis
   10.4 Government Policies
   10.5 Investment Scenario
Chapter 11 North America Patient Derived Xenograft (PDX) Models Analysis and Forecast
   11.1 Introduction
   11.2 North America Patient Derived Xenograft (PDX) Models Market Size Forecast by Country
      11.2.1 U.S.
      11.2.2 Canada
   11.3 Basis Point Share (BPS) Analysis by Country
   11.4 Absolute $ Opportunity Assessment by Country
   11.5 Market Attractiveness Analysis by Country
   11.6 North America Patient Derived Xenograft (PDX) Models Market Size Forecast By Type
      11.6.1 Mice Models
      11.6.2 Rat Models
   11.7 Basis Point Share (BPS) Analysis By Type
   11.8 Absolute $ Opportunity Assessment By Type
   11.9 Market Attractiveness Analysis By Type
   11.10 North America Patient Derived Xenograft (PDX) Models Market Size Forecast By Tumor Type
      11.10.1 Gastrointestinal Tumor Models
      11.10.2 Gynecological Tumor Models
      11.10.3 Respiratory Tumor Models
      11.10.4 Urological Tumor Models
      11.10.5 Hematological Tumor Models
      11.10.6 Others
   11.11 Basis Point Share (BPS) Analysis By Tumor Type
   11.12 Absolute $ Opportunity Assessment By Tumor Type
   11.13 Market Attractiveness Analysis By Tumor Type
   11.14 North America Patient Derived Xenograft (PDX) Models Market Size Forecast By Application
      11.14.1 Preclinical Drug Development
      11.14.2 Biomarker Analysis
      11.14.3 Basic Cancer Research
   11.15 Basis Point Share (BPS) Analysis By Application
   11.16 Absolute $ Opportunity Assessment By Application
   11.17 Market Attractiveness Analysis By Application
   11.18 North America Patient Derived Xenograft (PDX) Models Market Size Forecast By End-user
      11.18.1 Pharmaceutical & Biotechnology Companies
      11.18.2 Contract Research Organizations (CROs)
      11.18.3 Academic & Research Institutions
   11.19 Basis Point Share (BPS) Analysis By End-user
   11.20 Absolute $ Opportunity Assessment By End-user
   11.21 Market Attractiveness Analysis By End-user
Chapter 12 Europe Patient Derived Xenograft (PDX) Models Analysis and Forecast
   12.1 Introduction
   12.2 Europe Patient Derived Xenograft (PDX) Models Market Size Forecast by Country
      12.2.1 Germany
      12.2.2 France
      12.2.3 Italy
      12.2.4 U.K.
      12.2.5 Spain
      12.2.6 Russia
      12.2.7 Rest of Europe
   12.3 Basis Point Share (BPS) Analysis by Country
   12.4 Absolute $ Opportunity Assessment by Country
   12.5 Market Attractiveness Analysis by Country
   12.6 Europe Patient Derived Xenograft (PDX) Models Market Size Forecast By Type
      12.6.1 Mice Models
      12.6.2 Rat Models
   12.7 Basis Point Share (BPS) Analysis By Type
   12.8 Absolute $ Opportunity Assessment By Type
   12.9 Market Attractiveness Analysis By Type
   12.10 Europe Patient Derived Xenograft (PDX) Models Market Size Forecast By Tumor Type
      12.10.1 Gastrointestinal Tumor Models
      12.10.2 Gynecological Tumor Models
      12.10.3 Respiratory Tumor Models
      12.10.4 Urological Tumor Models
      12.10.5 Hematological Tumor Models
      12.10.6 Others
   12.11 Basis Point Share (BPS) Analysis By Tumor Type
   12.12 Absolute $ Opportunity Assessment By Tumor Type
   12.13 Market Attractiveness Analysis By Tumor Type
   12.14 Europe Patient Derived Xenograft (PDX) Models Market Size Forecast By Application
      12.14.1 Preclinical Drug Development
      12.14.2 Biomarker Analysis
      12.14.3 Basic Cancer Research
   12.15 Basis Point Share (BPS) Analysis By Application
   12.16 Absolute $ Opportunity Assessment By Application
   12.17 Market Attractiveness Analysis By Application
   12.18 Europe Patient Derived Xenograft (PDX) Models Market Size Forecast By End-user
      12.18.1 Pharmaceutical & Biotechnology Companies
      12.18.2 Contract Research Organizations (CROs)
      12.18.3 Academic & Research Institutions
   12.19 Basis Point Share (BPS) Analysis By End-user
   12.20 Absolute $ Opportunity Assessment By End-user
   12.21 Market Attractiveness Analysis By End-user
Chapter 13 Asia Pacific Patient Derived Xenograft (PDX) Models Analysis and Forecast
   13.1 Introduction
   13.2 Asia Pacific Patient Derived Xenograft (PDX) Models Market Size Forecast by Country
      13.2.1 China
      13.2.2 Japan
      13.2.3 South Korea
      13.2.4 India
      13.2.5 Australia
      13.2.6 South East Asia (SEA)
      13.2.7 Rest of Asia Pacific (APAC)
   13.3 Basis Point Share (BPS) Analysis by Country
   13.4 Absolute $ Opportunity Assessment by Country
   13.5 Market Attractiveness Analysis by Country
   13.6 Asia Pacific Patient Derived Xenograft (PDX) Models Market Size Forecast By Type
      13.6.1 Mice Models
      13.6.2 Rat Models
   13.7 Basis Point Share (BPS) Analysis By Type
   13.8 Absolute $ Opportunity Assessment By Type
   13.9 Market Attractiveness Analysis By Type
   13.10 Asia Pacific Patient Derived Xenograft (PDX) Models Market Size Forecast By Tumor Type
      13.10.1 Gastrointestinal Tumor Models
      13.10.2 Gynecological Tumor Models
      13.10.3 Respiratory Tumor Models
      13.10.4 Urological Tumor Models
      13.10.5 Hematological Tumor Models
      13.10.6 Others
   13.11 Basis Point Share (BPS) Analysis By Tumor Type
   13.12 Absolute $ Opportunity Assessment By Tumor Type
   13.13 Market Attractiveness Analysis By Tumor Type
   13.14 Asia Pacific Patient Derived Xenograft (PDX) Models Market Size Forecast By Application
      13.14.1 Preclinical Drug Development
      13.14.2 Biomarker Analysis
      13.14.3 Basic Cancer Research
   13.15 Basis Point Share (BPS) Analysis By Application
   13.16 Absolute $ Opportunity Assessment By Application
   13.17 Market Attractiveness Analysis By Application
   13.18 Asia Pacific Patient Derived Xenograft (PDX) Models Market Size Forecast By End-user
      13.18.1 Pharmaceutical & Biotechnology Companies
      13.18.2 Contract Research Organizations (CROs)
      13.18.3 Academic & Research Institutions
   13.19 Basis Point Share (BPS) Analysis By End-user
   13.20 Absolute $ Opportunity Assessment By End-user
   13.21 Market Attractiveness Analysis By End-user
Chapter 14 Latin America Patient Derived Xenograft (PDX) Models Analysis and Forecast
   14.1 Introduction
   14.2 Latin America Patient Derived Xenograft (PDX) Models Market Size Forecast by Country
      14.2.1 Brazil
      14.2.2 Mexico
      14.2.3 Rest of Latin America (LATAM)
   14.3 Basis Point Share (BPS) Analysis by Country
   14.4 Absolute $ Opportunity Assessment by Country
   14.5 Market Attractiveness Analysis by Country
   14.6 Latin America Patient Derived Xenograft (PDX) Models Market Size Forecast By Type
      14.6.1 Mice Models
      14.6.2 Rat Models
   14.7 Basis Point Share (BPS) Analysis By Type
   14.8 Absolute $ Opportunity Assessment By Type
   14.9 Market Attractiveness Analysis By Type
   14.10 Latin America Patient Derived Xenograft (PDX) Models Market Size Forecast By Tumor Type
      14.10.1 Gastrointestinal Tumor Models
      14.10.2 Gynecological Tumor Models
      14.10.3 Respiratory Tumor Models
      14.10.4 Urological Tumor Models
      14.10.5 Hematological Tumor Models
      14.10.6 Others
   14.11 Basis Point Share (BPS) Analysis By Tumor Type
   14.12 Absolute $ Opportunity Assessment By Tumor Type
   14.13 Market Attractiveness Analysis By Tumor Type
   14.14 Latin America Patient Derived Xenograft (PDX) Models Market Size Forecast By Application
      14.14.1 Preclinical Drug Development
      14.14.2 Biomarker Analysis
      14.14.3 Basic Cancer Research
   14.15 Basis Point Share (BPS) Analysis By Application
   14.16 Absolute $ Opportunity Assessment By Application
   14.17 Market Attractiveness Analysis By Application
   14.18 Latin America Patient Derived Xenograft (PDX) Models Market Size Forecast By End-user
      14.18.1 Pharmaceutical & Biotechnology Companies
      14.18.2 Contract Research Organizations (CROs)
      14.18.3 Academic & Research Institutions
   14.19 Basis Point Share (BPS) Analysis By End-user
   14.20 Absolute $ Opportunity Assessment By End-user
   14.21 Market Attractiveness Analysis By End-user
Chapter 15 Middle East & Africa (MEA) Patient Derived Xenograft (PDX) Models Analysis and Forecast
   15.1 Introduction
   15.2 Middle East & Africa (MEA) Patient Derived Xenograft (PDX) Models Market Size Forecast by Country
      15.2.1 Saudi Arabia
      15.2.2 South Africa
      15.2.3 UAE
      15.2.4 Rest of Middle East & Africa (MEA)
   15.3 Basis Point Share (BPS) Analysis by Country
   15.4 Absolute $ Opportunity Assessment by Country
   15.5 Market Attractiveness Analysis by Country
   15.6 Middle East & Africa (MEA) Patient Derived Xenograft (PDX) Models Market Size Forecast By Type
      15.6.1 Mice Models
      15.6.2 Rat Models
   15.7 Basis Point Share (BPS) Analysis By Type
   15.8 Absolute $ Opportunity Assessment By Type
   15.9 Market Attractiveness Analysis By Type
   15.10 Middle East & Africa (MEA) Patient Derived Xenograft (PDX) Models Market Size Forecast By Tumor Type
      15.10.1 Gastrointestinal Tumor Models
      15.10.2 Gynecological Tumor Models
      15.10.3 Respiratory Tumor Models
      15.10.4 Urological Tumor Models
      15.10.5 Hematological Tumor Models
      15.10.6 Others
   15.11 Basis Point Share (BPS) Analysis By Tumor Type
   15.12 Absolute $ Opportunity Assessment By Tumor Type
   15.13 Market Attractiveness Analysis By Tumor Type
   15.14 Middle East & Africa (MEA) Patient Derived Xenograft (PDX) Models Market Size Forecast By Application
      15.14.1 Preclinical Drug Development
      15.14.2 Biomarker Analysis
      15.14.3 Basic Cancer Research
   15.15 Basis Point Share (BPS) Analysis By Application
   15.16 Absolute $ Opportunity Assessment By Application
   15.17 Market Attractiveness Analysis By Application
   15.18 Middle East & Africa (MEA) Patient Derived Xenograft (PDX) Models Market Size Forecast By End-user
      15.18.1 Pharmaceutical & Biotechnology Companies
      15.18.2 Contract Research Organizations (CROs)
      15.18.3 Academic & Research Institutions
   15.19 Basis Point Share (BPS) Analysis By End-user
   15.20 Absolute $ Opportunity Assessment By End-user
   15.21 Market Attractiveness Analysis By End-user
Chapter 16 Competition Landscape
   16.1 Patient Derived Xenograft (PDX) Models Market: Competitive Dashboard
   16.2 Global Patient Derived Xenograft (PDX) Models Market: Market Share Analysis, 2019
   16.3 Company Profiles (Details - Overview, Financials, Developments, Strategy)
      16.3.1 Abnova Corporation
      16.3.2 Aragen Bioscience, a GVKBIO Company
      16.3.3 Bioduro
      16.3.4 Champions Oncology, Inc.
      16.3.5 Charles River Laboratories
      16.3.6 Envigo
      16.3.7 EPO Berlin-Buch GmbH
      16.3.8 Explora BioLabs
      16.3.9 Hera Biolabs
      16.3.10 NexusPharma
      16.3.11 Oncodesign
      16.3.12 THE JACKSON LABORATORY
      16.3.13 Urosphere
      16.3.14 WuXi AppTec
      16.3.15 Xentech
Key Segments Covered
By Type
  • Mice Models
  • Rat Models
By Tumor Type
  • Gastrointestinal Tumor Models
  • Gynecological Tumor Models
  • Respiratory Tumor Models
  • Urological Tumor Models
  • Hematological Tumor Models
  • Others
By Application
  • Preclinical Drug Development
  • Biomarker Analysis
  • Basic Cancer Research
By End-user
  • Pharmaceutical & Biotechnology Companies
  • Contract Research Organizations (CROs)
  • Academic & Research Institutions
By Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Key Market Players Profiled in the Report
  • Abnova Corporation
  • Aragen Bioscience, a GVKBIO Company
  • Bioduro
  • Champions Oncology, Inc.
  • Charles River Laboratories
  • Envigo
  • EPO Berlin-Buch GmbH
  • Explora BioLabs
  • Hera Biolabs
  • NexusPharma
  • Oncodesign
  • THE JACKSON LABORATORY
  • Urosphere
  • WuXi AppTec
  • Xentech
  • Top players in the market include THE JACKSON LABORATORY, WuXi AppTec, Envigo, Oncodesign, and Charles River Laboratories. These companies are considered as key manufacturers of Patient Derived Xenograft (PDX) Models based on their revenue, research development (R&D) activities, product offerings, regional presence, and supply chain management system.
  • The players are adopting key strategies such as acquisition, collaborations, and geographical expansion where potential opportunity for the Patient Derived Xenograft (PDX) Models market.
  • On March 02, 2021, Explora BioLabs launched two facilities in San Diego, in the US. The launch of these facilities is expected to expand Explora BioLabs’s footprints in San Diego from seven to nine on-demand vivaria.
  • On February 25, 2021, Charles River Laboratories, entered into a strategic partnership with Kibur Medical to offer exclusive access to its implantable microdevice (IMD) for in vivo preclinical oncology studies. Through this partnership, together with leading expertise in early-stage preclinical testing, researchers can utilize the Kibur technology to perform in vivo testing of multiple doses and multiple combinations of oncology or immune-oncology therapies in small cohorts of patient-derived xenograft (PDX), cell-line derived or syngeneic models.
  • In January 2021, Endo International plc launched Authorized Generic Version of Amitiza (lubiprostone) Capsules in the US.
Patient Derived Xenograft (PDX) Models Market By Key Players

Buy Report

FAQ Section

Some frequently asked quetions about this report!

Additional company profiles can be provided on request

According to this Growth Market Reports, the Patient Derived Xenograft (PDX) Models market is likely to register a CAGR of 14.5% during forecast period 2020-2027, with an anticipated valuation of USD 283.3 million by the end of the 2027.

In addition to market size (in US$ Million), Company Market Share (in % for base year 2019), Regulatory Landscape, Technology Landscape, Patent Analysis, Consumer Survey, and Pipeline/Clinical Trial Analysis.

Rising governments support for pharmaceutical and biotechnology industries, growing demand for personalized medicines, increasing R&D activities by pharmaceutical and biotechnology companies, and surging number of preclinical studies for developing anti-cancer drugs for solid tumors are the factors expected to drive the market growth during forecast period.

Usage of PDX model in preclinical drug development, biomarker analysis, and basic cancer research studies are the major applications of the Patient Derived Xenograft (PDX) Models.

Factors such as competitive strength and market positioning are key areas considered while selecting top companies to be profiled.

The market is expected to show decline of -3.2% in growth market between 2019 and 2020 owing to the COVID 19 pandemic effect on the Patient Derived Xenograft (PDX) Models market.

The base year considered for the Global Patient Derived Xenograft (PDX) Models market report is 2019. The complete analysis period is 2017 to 2027, wherein, 2017, and 2018 are the historic years, and the forecast is provided from 2020 to 2027.

Factors such as Surgical Treatment, Healthcare Expenditure, Technological Advancements, Export & Import Scenario, Price of Drugs, and GDP are analyzed in the final report.

Major manufactures include, THE JACKSON LABORATORY, WuXi AppTec, Envigo, Oncodesign, Charles River Laboratories, Explora BioLabs, Champions Oncology, Inc. and others.